Evidence map›Paper›PMID 35300565›Full record

ArticleBioengineered2022

MicroRNA miR-124-3p suppresses proliferation and epithelial-mesenchymal transition of hepatocellular carcinoma via ARRDC1 (arrestin domain containing 1).

Qiannan Zhao, Fen Jiang, Hui Zhuang, Yanfeng Chu, Fang Zhang, Chenghong Wang

Open access · goldAbstract read
In one paragraph

Article in Bioengineered, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Molecular medicine reports · 2025
    Article
  5. Article
  6. Article
  7. Advanced biomedical research · 2025
    Review
  8. Double-side role of short chain fatty acids on host health via the gut-organ axes.Animal nutrition (Zhongguo xu mu shou yi xue hui) · 2024
    Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Qiannan ZhaoDepartment of Laboratory Medicine, Yantai Mountain Hospital, Yantai, Shandong, China.
Fen JiangHealth Management Center, Qishan Hospital, Yantai, Shandong, China.
Hui ZhuangCentral Blood Station Laboratory, Yantai, Shandong, China.
Yanfeng ChuDepartment of Laboratory Medicine, Yantai Mountain Hospital, Yantai, Shandong, China.
Fang ZhangClinical Laboratory, Jinan Central Hospital, Qilu Medical College, Shandong University, Jinan, Shandong, China.
Chenghong WangDepartment of Laboratory Medicine, Yantai Mountain Hospital, Yantai, Shandong, China.
Yantaishan Hospital · CNJinan Central Hospital · CNYancheng Central Blood Station · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is responsible for high morbidity and mortality worldwide. Increasing evidence suggests that microRNAs intensively participate in HCC development and progression. In the current study, we aimed to explore the impact of miR-124-3p in the proliferation and epithelial-mesenchymal transition (EMT) of HCC. The RT-qPCR assay was employed to determine miR-124-3p expression in human HCC specimens and cell lines. Luciferase assay was used to validate the miR-124-3p target gene. Western Blot and RT-qPCR were performed to study the effects of miR-124-3p modulation on ARRDC1 (Arrestin Domain Containing 1) mRNA and protein expressions. MTT assay, wound healing assay, EdU assay, and Transwell assay were utilized to verify the impact of miR-144-3p modulation on HCC proliferation and EMT via ARRDC1. We found that MiR-124-3p expression downregulates in HCC. Overexpression of miR-124-3p reduced the HCC cell proliferation and EMT. Meanwhile, we determined that the expression of ARRDC1 is increased in HCC, and miR-124-3p directly binds the 3'UTR of ARRDC1 and inhibits its expression at mRNA and protein level, suggesting that miR-124-3p was capable of negatively modulating ARRDC1. Besides, cotransfection of ARRDC1-overexpression plasmid and miR-124-3p mimics increased the cell proliferation and EMT as compared to miR-124-3p mimics. Our study concluded that miR-124-3p directly binds the 3'UTR of ARRDC1 and exerts anti-tumorous effects by inhibiting the HCC proliferation and EMT. Therefore, miR-124-3p/ARRDC1 axis may serve as a novel therapeutic target to inhibit HCC growth and metastasis.

Indexed as

ArrestinsCarcinoma, HepatocellularLiver NeoplasmsMicroRNAs3' Untranslated RegionsCell Line, TumorCell MovementCell ProliferationEpithelial-Mesenchymal TransitionHumans3' Untranslated RegionsARRDC1 protein, humanArrestinsMicroRNAsMIRN124 microRNA, humanepithelial–mesenchymal transitionhepatocellular carcinomamicroRNAproliferation

Identifiers

PMID35300565
PMCPMC9161870
OpenAlexW4220776927

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.